"HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES."
Application 7058/DELNP/2006 published 2007-07-13, filed 2006-11-24
Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (l-4C)alkyl and HET-2; R5 is hydrogen or (l-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.
Applicant
1)Astrazeneca AB.
:S-151 85 SODERTALJE, SWEDEN Sweden
Inventor
1)CRAIG JOHNSTONE 2)DARREN MCKERRECHER 3)KURT GORDON PIKE 4)MICHAEL JAMES WARING
International Info
Classification: A61K 31/415 ,C07D 277/46
Publication Number: WO 2005/121110
Application Date: 1900-01-01
Priority Information
0412602.5 U.K. 2004-06-05